Catalysts
PCVX Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
PCVXVaxcyte, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum81
- Value—
- Quality54
- Risk resilience53
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 81/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 29.26%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | — | -$2.11 | -$1.99 | +5.7% | $12.5M | — |
| Aug 5, 2026 | — | -$2.06 | -$1.97 | +4.4% | $12.5M | — |
| May 6, 2026 | — | -$1.78 | -$2.30 | -29.4% | $12.5M | — |
| Feb 24, 2026 | — | -$1.53 | -$1.80 | -17.7% | $18.75M | — |
| Nov 4, 2025 | — | -$1.27 | -$1.56 | -22.8% | — | — |
| Aug 6, 2025 | — | -$1.12 | -$1.22 | -8.9% | — | — |
| May 7, 2025 | — | -$1.02 | -$1.04 | -2.0% | — | — |
| Feb 25, 2025 | — | -$1.16 | -$1.02 | +12.1% | — | — |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances
2026 has been a breakout year for Vaxcyte Inc. (PCVX), with a string of positive pipeline developments lending its shares fresh momentum. With multiple clinical readouts on the horizon, the company's 2027 calendar could prove pivotal for its pneumococcal vaccine ambitions.
Related Links
PCVX Catalysts FAQ
What are the next catalysts for PCVX stock?
PCVX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move PCVX stock?
Upcoming events that could move PCVX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could PCVX's next earnings report affect the stock?
PCVX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive PCVX stock higher?
PCVX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt PCVX stock?
PCVX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.